130 related articles for article (PubMed ID: 8897699)
1. Autoantibodies to kininogen-phosphatidylethanolamine complexes augment thrombin-induced platelet aggregation.
Sugi T; McIntyre JA
Thromb Res; 1996 Oct; 84(2):97-109. PubMed ID: 8897699
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies.
Sugi T; Mclntyre JA
Thromb Haemost; 1996 Sep; 76(3):354-60. PubMed ID: 8883270
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies to Factor XII and Kininogen-Dependent Antiphosphatidylethanolamine Antibodies in Patients with Recurrent Pregnancy Loss Augment Platelet Aggregation.
Sato Y; Sugi T; Sakai R
Am J Reprod Immunol; 2015 Sep; 74(3):279-89. PubMed ID: 26011374
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex.
Sugi T; McIntyre JA
Blood; 1995 Oct; 86(8):3083-9. PubMed ID: 7579402
[TBL] [Abstract][Full Text] [Related]
5. Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens.
Sugi T; McIntyre JA
J Autoimmun; 2001 Nov; 17(3):207-14. PubMed ID: 11712858
[TBL] [Abstract][Full Text] [Related]
6. High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets.
Puri RN; Zhou F; Hu CJ; Colman RF; Colman RW
Blood; 1991 Feb; 77(3):500-7. PubMed ID: 1846761
[TBL] [Abstract][Full Text] [Related]
7. Human kininogens regulate thrombin binding to platelets through the glycoprotein Ib-IX-V complex.
Bradford HN; Dela Cadena RA; Kunapuli SP; Dong JF; Löpez JA; Colman RW
Blood; 1997 Aug; 90(4):1508-15. PubMed ID: 9269768
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation.
Meloni FJ; Schmaier AH
J Biol Chem; 1991 Apr; 266(11):6786-94. PubMed ID: 2016293
[TBL] [Abstract][Full Text] [Related]
9. Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 of domain 3 in the heavy chain of high molecular weight kininogen.
Kunapuli SP; Bradford HN; Jameson BA; DeLa Cadena RA; Rick L; Wassell RP; Colman RW
J Biol Chem; 1996 May; 271(19):11228-35. PubMed ID: 8626672
[TBL] [Abstract][Full Text] [Related]
10. Kininogen domain 3 contains regions recognized by antiphosphatidylethanolamine antibodies.
Katsunuma J; Sugi T; Inomo A; Matsubayashi H; Izumi SI; Makino T
J Thromb Haemost; 2003 Jan; 1(1):132-8. PubMed ID: 12871550
[TBL] [Abstract][Full Text] [Related]
11. Modulation of thrombin-induced platelet aggregation by inhibition of calpain by a synthetic peptide derived from the thiol-protease inhibitory sequence of kininogens and S-(3-nitro-2-pyridinesulfenyl)-cysteine.
Puri RN; Matsueda R; Umeyama H; Bradford HN; Colman RW
Eur J Biochem; 1993 May; 214(1):233-41. PubMed ID: 8389701
[TBL] [Abstract][Full Text] [Related]
12. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets.
Jiang YP; Muller-Esterl W; Schmaier AH
J Biol Chem; 1992 Feb; 267(6):3712-7. PubMed ID: 1740422
[TBL] [Abstract][Full Text] [Related]
13. High-molecular-mass and low-molecular-mass kininogens block plasmin-induced platelet aggregation by forming a complex with kringle 5 of plasminogen/plasmin.
Selim TE; Ghoneim HR; Uknis AB; Colman RW; DeLa Cadena RA
Eur J Biochem; 1997 Dec; 250(2):532-8. PubMed ID: 9428707
[TBL] [Abstract][Full Text] [Related]
14. High-molecular weight kininogen. A secreted platelet protein.
Schmaier AH; Zuckerberg A; Silverman C; Kuchibhotla J; Tuszynski GP; Colman RW
J Clin Invest; 1983 May; 71(5):1477-89. PubMed ID: 6406551
[TBL] [Abstract][Full Text] [Related]
15. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies detected by ELISA. II. Kininogen reactivity.
Boffa MC; Berard M; Sugi T; McIntyre JA
J Rheumatol; 1996 Aug; 23(8):1375-9. PubMed ID: 8856616
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of thrombin-induced platelet aggregation by high molecular weight kininogen.
Puri RN; Gustafson EJ; Zhou FX; Bradford H; Colman RF; Colman RW
Trans Assoc Am Physicians; 1987; 100():232-40. PubMed ID: 3455067
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of a kininogen-based selective inhibitor of thrombin-induced platelet aggregation.
Matsueda R; Umeyama H; Puri RN; Bradford HN; Colman RW
Pept Res; 1994; 7(1):32-5. PubMed ID: 8019060
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of thrombin- and plasmin-induced platelet aggregation by a synthetic peptide disulfide.
Puri RN; Hu CJ; Bradford HN; Matsueda R; Umeyama H; Colman RW
Trans Assoc Am Physicians; 1989; 102():13-9. PubMed ID: 2561638
[TBL] [Abstract][Full Text] [Related]
19. Potential pharmacological applications of the antithrombotic molecule high molecular weight kininogen.
Chavakis T; Preissner KT
Curr Vasc Pharmacol; 2003 Mar; 1(1):59-64. PubMed ID: 15320853
[TBL] [Abstract][Full Text] [Related]
20. An autoantibody directed against human thrombin anion-binding exosite in a patient with arterial thrombosis: effects on platelets, endothelial cells, and protein C activation.
Arnaud E; Lafay M; Gaussem P; Picard V; Jandrot-Perrus M; Aiach M; Rendu F
Blood; 1994 Sep; 84(6):1843-50. PubMed ID: 8080990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
